XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.23.1

Other Balance Sheet Information | 3 Months Ended
--- | ---
Apr. 01, 2023
Balance Sheet Related Disclosures [Abstract] |
Other Balance Sheet Information | Other Balance Sheet Information
| April 1, 2023 |  | September 24, 2022
Inventories |  |  |
Raw materials | $ | 293.3 |  |  | $ | 252.9 |
Work-in-process | 65.8 |  |  | 60.1 |
Finished goods | 328.5 |  |  | 310.7 |
| $ | 687.6 |  |  | $ | 623.7 |
Property, plant and equipment |  |  |
Equipment | $ | 407.6 |  |  | $ | 394.8 |
Equipment under customer usage agreements | 506.8 |  |  | 486.5 |
Building and improvements | 206.2 |  |  | 196.0 |
Leasehold improvements | 47.1 |  |  | 44.8 |
Land | 41.1 |  |  | 40.9 |
Furniture and fixtures | 19.2 |  |  | 16.7 |
Finance lease right of use asset | 8.4 |  |  | 7.5 |
| $ | 1,236.4 |  |  | $ | 1,187.2 |
Less – accumulated depreciation and amortization | (738.5) |  |  | (705.6) |
| $ | 497.9 |  |  | $ | 481.6 |
In September 2020 and October 2020, the Company was awarded grants of $7.6 million and $119.3 million, respectively, from the Department of Defense Joint Acquisition Task Force (“DOD”) to expand production capacity for the Company’s two SARS-CoV-2 assays. These grants were specifically to fund capital equipment and labor investments to increase manufacturing capacity to enable the Company to provide a certain amount of COVID-19 tests per month for the U.S. market. The Company has accounted for the funds received under these grants as a reimbursement of the purchased capital equipment. The Company procured and paid for the capital equipment and necessary resources to build out its facility and construct the manufacturing lines to meet the requirements specified in the grant agreement. Subsequent to the Company paying for the capital equipment, the DOD reimbursed the Company upon it meeting certain requirements. However, the DOD retained title to the assets purchased under the agreement, and title was transferred to the Company upon meeting certain milestones of the manufacturing efforts and obtaining approval from the DOD that the respective milestone had been met. As of the end of fiscal 2022, the Company had completed all milestones under the agreement and was waiting for approval by the DOD. During the second quarter of fiscal 2023, the Company received the final DOD approvals and the final payment from the DOD of $20.5 million, which was recorded as a reduction of the cost basis of the purchased equipment. As of April 1, 2023, no other amounts were awaiting approval and all defined milestones were completed.

X
- Definition Details of certain balance sheet accounts. + References No definition available. + Details
Name: | holx_DetailsOfCertainBalanceSheetAccountsTextBlock
Namespace Prefix: | holx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration